Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA known ✓ | P35790 | 2/20 | 0.55 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.49 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.38 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2912607 | 0.98 | CHKA (0.53) | CHKABCHEACHECA2CAMK2A | |
| Bromide SCHEMBL3874382 | 0.80 | CA2 (0.44) | CA2CAMK2AAKR1B1LMNAGAA | |
| Bromide SCHEMBL6889492 | 0.78 | BCHE (0.68) | CHKABCHEACHELMNAKMT2A | |
| SCHEMBL2911873 | 0.78 | CA2 (0.46) | CA2CAMK2AAKR1B1LMNAGAA | |
| SCHEMBL2344944 | 0.76 | BCHE (0.65) | CHKABCHEACHEKMT2ACHRM2 | |
| Water SCHEMBL31012149 | 0.74 | BCHE (0.62) | CHKABCHEACHEKMT2ACHRM2 | |
| SCHEMBL14031427 | 0.73 | CHKA (0.59) | CHKABCHEACHEALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL10997929 | 0.72 | CHKA (0.57) | CHKABCHEACHELMNAALDH1A1 | |
| SCHEMBL69614 | 0.71 | CA2 (0.79) | CA2CAMK2AAKR1B1LMNAGAA | |
| Hydrochloric Acid SCHEMBL25180348 | 0.69 | CA2 (0.75) | CA2CAMK2AAKR1B1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579339-B2 | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-08-25 | — | — | US | disclosed |
| US-7407938-B2 | 1,4-Diphenyl-3-(3-hydroxy-3-phenylpropyl)-2-azetidinones, e.g., 2,3,4,5,6-Pentahydroxyhexylamide of 4-(4-{4-[3-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1-y]lbenzylcarbamoyl}phenoxy)benzoic acid; antilipemic agents that have intestinal absorption of less than 10%, | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-08-05 | — | — | US | disclosed |
| US-7390790-B2 | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-06-24 | — | — | US | disclosed |
| US-20070043017-A1 | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH | 2007-02-22 | — | — | US | disclosed |
| US-20070037787-A1 | 1,4-Diphenyl-3-(3-hydroxy-3-phenylpropyl)-2-azetidinones, e.g., 2,3,4,5,6-Pentahydroxyhexylamide of 4-(4-{4-[3-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1-y]lbenzylcarbamoyl}phenoxy)benzoic acid; antilipemic agents that have intestinal absorption of less than 10%, | SANOFI-AVENTIS DEUTSCHLAND GMBH | 2007-02-15 | — | — | US | disclosed |
| US-7176194-B2 | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-02-13 | — | — | US | disclosed |
| US-20060270613-A1 | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH | 2006-11-30 | — | — | US | disclosed |
| US-20040082561-A1 | Ring -substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043017-A1 | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | QDPR, CYP2D6, DHCR7 | CHKA 2681/4885ACHE 1627/4885CHRM2 1722/4885 |
| US-20040082561-A1 | Ring -substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | QDPR, CYP2D6, DHCR7 | CHKA 2914/4885ACHE 1526/4885CHRM2 1532/4885 |
| US-20060270613-A1 | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | QDPR, CYP2D6, DHCR7 | CHKA 2681/4885ACHE 1627/4885CHRM2 1722/4885 |
| US-20070037787-A1 | 1,4-Diphenyl-3-(3-hydroxy-3-phenylpropyl)-2-azetidinones, e.g., 2,3,4,5,6-Pentahydroxyhexylamide of 4-(4-{4-[3-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1-y]lbenzylcarbamoyl}phenoxy)benzoic acid; antilipemic agents that have intestinal absorption of less than 10%, | HPD, FABP2, CYP2B6 | CHKA 2528/4885ACHE 2830/4885CHRM2 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.